AKBA News and Press, Akebia Therapeutics Inc. From 10/29/25

A look at the top 10 most actives in the United States Cambium Networks Corporation (CMBM) rose 270.6% to $2.29 on volume of 218,383,326 shares Purple Biotech Ltd. (PPBT) rose 95.5% to $1.14 on volume of 186,196,940 shares Profusa Inc. (PFSA) rose 27.2% to $0.36895 on volume of 117,196,177 ...

2025-10-29 05:01:32 ET More on related stocks: Soaring Potential: Why Aggressive Investors Should Take A Closer Look At Joby Aviation Enphase Energy, Inc. (ENPH) Q3 2025 Earnings Call Transcript Joby Aviation: Technology Advantage Now Reflected In The Share Price ...

2025-10-28 17:45:05 ET More on Akebia Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection Akebia Therapeutics, Inc...

CAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that after meeting with the U.S. Food and Drug Administration (FDA) it has...

CAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney W...

2025-09-05 01:34:58 ET Akebia Therapeutics, Inc. (AKBA) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:00 AM EDT... Read the full article on Seeking Alpha For further details see: Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual He...

2025-08-28 08:17:12 ET Thesis At $3.13 a share, I’m pretty bullish on Akebia ( AKBA ) stock. The 21% sell-off after Q2 earnings looks more like an overreaction than a red flag to me. Sure, the EPS quality wasn’t perfect, but the growth was undeniable, and Vafse...

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two inve...

2025-08-07 19:34:39 ET More on Akebia Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026 Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Be...

2025-08-07 19:34:09 ET Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Conference Call August 07, 2025 08:00 AM ET Company Participants Erik John Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer John P. Butler - CEO, President & Director M...